Lucy A Godley Selected Research

5-hydroxymethylcytosine

1/2020	5-Hydroxymethylcytosine Profiles in Circulating Cell-Free DNA Associate with Disease Burden in Children with Neuroblastoma.
1/2019	5-Hydroxymethylcytosine Profiles Are Prognostic of Outcome in Neuroblastoma and Reveal Transcriptional Networks That Correlate With Tumor Phenotype.
11/2016	Integrative genomics reveals hypoxia inducible genes that are associated with a poor prognosis in neuroblastoma patients.
1/2016	Corrigendum: TET-catalyzed 5-hydroxymethylcytosine regulates gene expression in differentiating colonocytes and colon cancer.
12/2015	TET-catalyzed 5-hydroxymethylcytosine regulates gene expression in differentiating colonocytes and colon cancer.
7/2015	TET2 Mutations Affect Non-CpG Island DNA Methylation at Enhancers and Transcription Factor-Binding Sites in Chronic Myelomonocytic Leukemia.
5/2015	5-hydroxymethylcytosine in cancer: significance in diagnosis and therapy.
6/2013	Alterations of 5-hydroxymethylcytosine in human cancers.
1/2013	Perturbations of 5-hydroxymethylcytosine patterning in hematologic malignancies.
9/2011	Inhibition of TET2-mediated conversion of 5-methylcytosine to 5-hydroxymethylcytosine disturbs erythroid and granulomonocytic differentiation of human hematopoietic progenitors.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Lucy A Godley Research Topics

Disease

42	Neoplasms (Cancer) 01/2022 - 11/2002
16	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 01/2020 - 11/2002
9	Leukemia 11/2021 - 11/2002
7	Hematologic Neoplasms (Hematological Malignancy) 01/2022 - 06/2012
7	Neuroblastoma 11/2021 - 09/2012
7	Myelodysplastic Syndromes (Myelodysplastic Syndrome) 01/2020 - 09/2007
5	Hypoxia (Hypoxemia) 01/2020 - 02/2012
5	Thrombocytopenia (Thrombopenia) 10/2019 - 12/2012
3	Lymphoma (Lymphomas) 04/2016 - 02/2011
3	Myeloid Leukemia (Leukemia, Myelocytic) 07/2015 - 08/2008
2	Cardiotoxicity 11/2021 - 01/2018
2	Hypersensitivity (Allergy) 10/2020 - 01/2016
2	Chronic Myelomonocytic Leukemia (Leukemia, Chronic Myelomonocytic) 01/2020 - 07/2015
2	Acute Promyelocytic Leukemia 11/2018 - 03/2015
2	Febrile Neutropenia 01/2018 - 04/2016
2	Multiple Myeloma 01/2018 - 07/2009
2	Neutropenia 04/2016 - 07/2013
2	Breast Neoplasms (Breast Cancer) 01/2016 - 01/2015
2	Colonic Neoplasms (Colon Cancer) 01/2016 - 12/2015
1	Triple Negative Breast Neoplasms 01/2022
1	Acute Erythroblastic Leukemia (Erythroleukemia) 12/2021
1	Retinoblastoma (Glioblastoma, Retinal) 11/2021
1	Bone Marrow Failure Disorders 10/2020
1	Interstitial Lung Diseases (Interstitial Lung Disease) 10/2020
1	Anorexia 01/2018
1	Diarrhea 01/2018
1	Bacteremia 01/2018
1	Fatigue 01/2018
1	Vomiting 01/2018
1	Nausea 01/2018
1	Autoimmune Diseases (Autoimmune Disease) 01/2017
1	Refractory Anemia with Excess of Blasts (RAEM) 04/2016
1	Pneumonia (Pneumonitis) 04/2016
1	Genomic Instability 01/2016
1	Fanconi Anemia (Fanconi's Anemia) 01/2016
1	Infections 01/2016

Drug/Important Bio-Agent (IBA)

19	DNA (Deoxyribonucleic Acid)IBA 01/2022 - 12/2010
10	Proteins (Proteins, Gene)FDA Link 11/2021 - 07/2009
10	5-hydroxymethylcytosineIBA 01/2020 - 09/2011
8	Decitabine FDA Link 01/2017 - 09/2007
4	EnzymesIBA 01/2020 - 12/2010
4	Mitoxantrone (Novantrone)FDA LinkGeneric 01/2020 - 06/2010
4	Cytarabine (Cytosar-U)FDA LinkGeneric 01/2020 - 06/2010
4	5-Methylcytosine (5 Methylcytosine)IBA 07/2015 - 09/2011
4	MethyltransferasesIBA 01/2015 - 09/2012
3	Azacitidine (5 Azacytidine)FDA Link 01/2020 - 04/2015
3	Biomarkers (Surrogate Marker)IBA 01/2020 - 11/2016
3	CytosineIBA 11/2014 - 01/2013
3	Protein Isoforms (Isoforms)IBA 03/2013 - 07/2010
3	Alemtuzumab (Campath)FDA Link 06/2012 - 12/2010
2	RNA (Ribonucleic Acid)IBA 11/2021 - 01/2019
2	Granulocyte Colony-Stimulating Factor (G-CSF)IBA 10/2020 - 11/2016
2	Tretinoin (Retinoic Acid)FDA LinkGeneric 11/2018 - 09/2012
2	Transcription Factors (Transcription Factor)IBA 08/2017 - 07/2015
2	Pharmaceutical PreparationsIBA 04/2016 - 07/2013
2	A-Form DNA (A-DNA)IBA 01/2015 - 08/2009
2	DioxygenasesIBA 06/2014 - 01/2014
2	alpha-hydroxyglutarateIBA 02/2013 - 12/2010
1	GlobinsIBA 12/2021
1	Type II DNA Topoisomerases (Topoisomerase II)IBA 11/2021
1	CX 5461IBA 11/2021
1	Topoisomerase I InhibitorsIBA 11/2021
1	tert-butylserineIBA 10/2020
1	Core Binding Factor Alpha 2 SubunitIBA 01/2020
1	Cell-Free Nucleic AcidsIBA 01/2020
1	Adenosine Monophosphate (AMP)IBA 10/2019
1	Arsenic Trioxide (Trisenox)FDA Link 11/2018
1	AnthracyclinesIBA 01/2018
1	Exportin 1 ProteinIBA 01/2018
1	ElectrolytesIBA 01/2018
1	Histones (Histone)IBA 01/2018
1	Lysine (L-Lysine)FDA Link 01/2018
1	selinexorIBA 01/2018
1	ChromatinIBA 11/2016
1	ON 01910IBA 04/2016
1	Tetracycline (Achromycin)FDA LinkGeneric 03/2016
1	Succinic Acid (Succinate)IBA 02/2016
1	Fumarate Hydratase (Fumarase)IBA 02/2016
1	Succinate Dehydrogenase (Fumarate Reductase)IBA 02/2016
1	FumaratesIBA 02/2016
1	Mitomycin (Mitomycin-C)FDA LinkGeneric 01/2016
1	Checkpoint Kinase 2IBA 01/2016
1	SteroidsIBA 01/2016
1	CohesinsIBA 11/2015
1	5-carboxylcytosineIBA 05/2015
1	5-formylcytosineIBA 05/2015
1	Histone Deacetylase InhibitorsIBA 04/2015
1	belinostatIBA 04/2015
1	HLA-DR Antigens (HLA-DR)IBA 03/2015

Therapy/Procedure

24	Therapeutics 01/2022 - 11/2002
5	Drug Therapy (Chemotherapy) 01/2022 - 08/2008
3	Hematopoietic Stem Cell Transplantation 01/2022 - 12/2012
2	Stem Cell Transplantation 01/2022 - 01/2017
2	Aftercare (After-Treatment) 11/2021 - 08/2008
1	Immunotherapy 11/2021
1	Cell Transplantation 01/2019
1	Homologous Transplantation 01/2019
1	Remission Induction 01/2018
1	Hematopoietic Stem Cell Mobilization 11/2016
1	Transplantation 03/2016